ESMO Gynaecological Cancers Congress 2023
![Michael A. Bookman](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/michael-a.-bookman/17249357-1-eng-GB/michael-a.-bookman_i770.jpg)
What are the consequences of ‘pandemomics’ in gynaecological cancers?
As science and innovations continue to progress in gynaecological oncology, there is a need to rethink our perceptions to ensure clinical management and research advance accordingly
![ESMO Gynae 2023_stage](/var/esmo/storage/images/media/esmo-daily-reporter/images/gynae-2023/esmo-gynae-2023_stage/17269940-1-eng-GB/esmo-gynae-2023_stage_i770.jpg)
Is ATR inhibition a potential new treatment for rare gynaecological cancers?
Ceralasertib, alone or in combination with PARP inhibition, showed signs of clinical efficacy in patients with relapsed ovarian and endometrial clear cell carcinomas (CCC), for whom effective treatment options are currently lacking
![ESMO Gynae 2023_people](/var/esmo/storage/images/media/esmo-daily-reporter/images/gynae-2023/esmo-gynae-2023_people/17269955-1-eng-GB/esmo-gynae-2023_people_i770.jpg)
Ovarian cancer: updated phase III data provide reassurance for the use of PARPi as maintenance therapy
Sustained benefit of PARPi treatment may help to put the recent concerns on how and when to use these agents in women into context
![ESMO Gynae 2023_Special Symposium](/var/esmo/storage/images/media/esmo-daily-reporter/images/gynae-2023/esmo-gynae-2023_special-symposium/17269925-1-eng-GB/esmo-gynae-2023_special-symposium_i770.jpg)
Is overall survival the right endpoint for PARPi trials in ovarian cancer?
Unfavourable overall survival data for PARP inhibitors in certain ovarian cancers prompts calls for caution in interpretation of the analyses and stimulates the search for surrogate measures of clinical benefit